SAVE SIGHT REGISTRIES PROJECT
Fight Tumour Blindness!
A web based registry for ocular melanoma, collecting clinical and pathology data to evaluate eye saving treatments and stratify patients for emerging systemic therapies.
OVERVIEW
A national registry for ocular melanoma
- Launched
- September 2018
- Redeveloped
- 2022, with leading Australian uveal melanoma experts
- Condition
- Ocular (uveal) melanoma
- Data
- Clinical, pathology, treatment and follow up
Melanoma of the eye threatens both vision and life. The eye is the second most common site of melanoma after the skin, and uveal melanoma is fatal in approximately 50% of cases because of metastatic spread.
Cancer registries in Australia are state based and collect only minimum information. The data needed to understand recurrence, metastasis and treatment success in eye melanoma is missing.
Fight Tumour Blindness! is an Australian first: a web based registry that embeds research within health care delivery, as recommended by the McKeon Strategic Review of Health and Medical Research (2013).
RESEARCH AIMS
What the registry sets out to do
AIM 1
Collect high quality clinical and pathology data from patients with ocular melanoma.
AIM 2
Evaluate the outcomes of local, conservative eye saving treatments.
AIM 3
Stratify patients for appropriate emerging therapies to combat potentially fatal systemic disease.
CLINICAL CONTEXT
Current approaches to treatment
Where possible, primary eye melanoma is treated conservatively to preserve the eye and vision while controlling the tumour. Treatments are often successful but may reduce vision or result in loss of the eye.
Management is multidisciplinary and varies widely across Australia, which is why detailed diagnostic, treatment and follow up data is essential.
| TREATMENT | TYPICAL USE |
|---|---|
| Plaque brachytherapy | The most common treatment, using iodine or ruthenium radiation, with or without customised plaque design and dosimetry planning |
| Trans scleral resection | Anterior segment and ciliary body tumours |
| Endo resection | Large posterior tumours |
| Transpupillary thermotherapy | Thinner, pigmented tumours |
| Photodynamic therapy | Thinner tumours |
INVESTIGATOR
Leading Fight Tumour Blindness!
CO INVESTIGATOR
Dr Rod O’Day
DMedSci, MBBS (Hons), LLB (Hons), BSc, FRANZCO
Head of Ocular Oncology Research, Centre for Eye Research Australia


